Clinical Trials Browser

Interventional × zimberelimab × Gynecologic × Clear all

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase 2 Active not recruiting

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07424664 2026-02-20

A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer

Phase 2 Not yet recruiting

30 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT06790706 2025-10-06

IMMUNORARE5

Phase 2 Recruiting

154 enrolled

EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT04772989 2025-08-28

ARC-12

Phase 1 Completed

94 enrolled

DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Phase 1 Completed

48 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

NCT06155396 2024-02-28

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Phase 2 Recruiting

116 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06128460 2023-11-30

Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.

Phase 2 Not yet recruiting

24 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06055738 2023-09-28

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Phase 2 Recruiting

20 enrolled

Gynecologic

Locally Advanced Cervical Cancer

NCT05872724 2023-05-24

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

Phase 2 Recruiting

32 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT03972722 2019-06-05

CC

Phase 2 Unknown

89 enrolled

Gynecologic

Uterine Cervical Neoplasms

Clinical Trials

ARC-25

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer

IMMUNORARE5

ARC-12

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

CC